04:36 AM EST, 11/13/2026 (MT Newswires) -- Cessatech (CETX.ST) said the European Medicines Agency's Committee for Medicinal Products for Human Use maintained its negative opinion on Proveca's marketing authorization application for CT001/KemSu as a ketamine/sufentanil nasal spray for acute pain in children, after a re-examination. The Danish pharmaceutical company and its commercialization partner plan to seek scientific advice from the EMA to clarify outstanding evidence gaps and determine the additional data needed for a potential resubmission, according to a Friday release. Cessatech added that the CHMP had removed one of the two original grounds for refusal, leaving one regulatory issue to address.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.